[1] Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J]. Cancer, 2010127):2893-2917.
[2] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012[J]. CA Cancer J Clin, 2012, 621):10-29.  doi: 10.3322/caac.20138
[3] Epstein JI, Partin AW, Sauvageot J, et al. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up[J]. Surg Pathol, 1996, 203):286-292.
[4] Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update[J]. JAMA, 1997, 27718):1445-1451.  doi: 10.1001/jama.1997.03540420041027
[5] Schroder FH, Hermanek P, Denis L, et al. The TNM classification of prostate cancer[J]. Prostate Suppl, 19924):129-138.
[6] Soylu FN, Eggener S, Oto A. Local staging of prostate cancer with MRI[J]. Diagn interv Radiol, 2012, 184):365-373.
[7] Tanaka H, Hayashi S, Ohtakara K, et al. Usefulness of CT-MRI fusion in radiotherapy planning for localized prostate cancer[J]. Radiat Res, 2011, 526):782-788.  doi: 10.1269/jrr.11053
[8] 晋晖. 3.0T磁共振对前列腺外周带癌的诊断价值[J].中国医疗前沿, 2013, 87):97-98.
[9] 李春媚, 陈敏, 李飒英, 等.前列腺癌MR动态增强扫描定量分析及其应用[J].中华放射学杂志, 2011, 455):508-5l0.  doi: 10.3760/cma.j.issn.1005-1201.2011.05.023
[10] Doo KW, Sung DJ, Park BJ, et al. Detectability of low and intermediate or high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI[J]. Eur Radiol, 2012, 228):1812-1819.  doi: 10.1007/s00330-012-2430-5
[11] 赵阳, 徐勇, 韩悦, 等. MR波谱成像对前列腺癌分化程度预估价值的初步研究[J].中华放射学杂志, 2011, 4510):951-954.  doi: 10.3760/cma.j.issn.1005-1201.2011.10.014
[12] Nix Jw, Turkhey B, Hoang A, et al.Very distal apical prostate tumors:identification on multiparametric MRI at 3 Tesla[J]. BJU Int, 2012, 11011 Pt B):694-700.
[13] Kaji Y, Kurhanewicz J, Hricak H, et al. Localizing prostate cancer in the presence of post biopsy changes on MR images:role of proton MR spectroscopic imaging[J]. Radiology, 1998, 2063):785-790.
[14] Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomogramsPartin Tables)for the new millennium[J]. Urology, 2001, 586):843-848.  doi: 10.1016/S0090-4295(01)01441-8
[15] Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate specific antigen level, clinical stage, and biopsy Gleason scorePartin tables)based on cases from 2000 to 2005[J]. Urology, 2007, 696):1095-1101.  doi: 10.1016/j.urology.2007.03.042
[16] Kattan MW. Re:Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy gleason scorePartin Tables) based on cases from 2000 to 2005[J]. Eur Urol, 2007, 525):1528.
[17] 高旭, 孙颖浩, 许传亮, 等.应用Partin tables预测国人前列腺癌术后病理特征准确性的研究[J].中华泌尿外科杂志, 2007, 289):614-618.  doi: 10.3760/j.issn:1000-6702.2007.09.010
[18] Ren J, Huan Y, Wang H, et al. Seminal vesicle invasion in prostate cancer:prediction with combined T2-weighted and diffusion-weighted MR imaging[J]. Eur Radiol, 2009, 1910):2481-2486.  doi: 10.1007/s00330-009-1428-0
[19] Wang YJ. Superparamagnetic iron oxide based MRI contrast agents:Current status of clinical application[J]. Quant Imaging Med Surg, 20111):35-40.
[20] Hentschel B, Oehler W, Strauss D, et al. Definition of the CTV prostate in CT and MRI by using CT-MRI image fusion in IMRT planning for prostate cancer[J]. Strahlenther Onkol, 2011, 1873):183-190.  doi: 10.1007/s00066-010-2179-1